FOXM1 and meningioma: First, it is well characterized in the literature that hypermitotic and immune-enriched meningiomas have highly unfavorable clinical outcomes, substantial cell proliferation, and carry nearly total resistance to cytotoxic therapies due to misactivation of FOXM1 and loss of Merlin/NF2.